AstraZeneca Receives Positive Opinion from EMA for COPD Treatment

AstraZeneca's COPD therapy, Trixeo Aerosphere, has received a positive opinion from the European Medicines Agency. The therapy uses a next-generation propellant with near-zero global warming potential, making it a more sustainable option for patients and the environment. This is a significant milestone in AstraZeneca's commitment to delivering innovations for sustainable healthcare in the EU.

AstraZeneca's COPD therapy, Trixeo Aerosphere, has received a positive opinion from the European Medicines Agency (EMA). The therapy, which uses a next-generation propellant with near-zero global warming potential (GWP), marks a significant milestone in AstraZeneca's commitment to sustainable healthcare in the EU.

Trixeo Aerosphere, a fixed-dose triple-combination therapy for chronic obstructive pulmonary disease (COPD), is the first medicine from AstraZeneca to transition to the next-generation propellant. This propellant offers a 99.9% reduction in GWP compared to current propellants used in pressurized metered-dose inhalers (pMDIs) [1].

The Committee for Medicinal Products for Human Use (CHMP) of the EMA has endorsed Trixeo Aerosphere with the next-generation propellant for use in the EU. The decision is based on clinical development program results demonstrating bioequivalence between Trixeo with the new propellant and the current propellant. The safety and tolerability profile for Trixeo with the next-generation propellant was consistent with the known profile of the medicine [1].

Frederik Trinkmann, a senior pulmonologist at the Thoracic Clinic at Heidelberg University Hospital, Germany, welcomed the transition, stating that it allows clinicians to focus on clinical needs while supporting environmental goals. Ruud Dobber, Executive Vice President of AstraZeneca's BioPharmaceuticals Business Unit, noted that this positive opinion allows AstraZeneca to address both patient needs and environmental concerns, aligning with their Ambition Zero Carbon strategy [1].

AstraZeneca plans to transition its wider pMDI portfolio to the near-zero GWP propellant by 2030. The company aims to initiate the transition of Trixeo to the next-generation propellant in the EU in the coming months. This transition is part of AstraZeneca's broader effort to reduce the carbon footprint of its respiratory medicines [1].

References:
[1] https://www.tradingview.com/news/reuters.com,2025-07-25:newsml_Wkr8BG3lP:0-trixeo-aerosphere-receives-positive-eu-chmp-opinion-as-first-inhaled-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential/